title: Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer.
abstract: •We present two cases of advanced uterine cancer that were treated with the combination of metronomic cyclophosphamide and bevacizumab.•Targeting angiogenesis can provide disease control in patients with advanced uterine cancer.•Randomized controlled trials comparing metronomic and conventional regimens in advanced uterine cancer are required.
authors.affiliation: Department of Gynecologic Oncology, SUNY-Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Alagkiozidis
authors.affiliation: Department of Gynecologic Oncology, SUNY-Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Lozano
authors.affiliation: Department of Gynecologic Oncology, SUNY-Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Mithun
authors.initials: M
authors.lastname: Devraj
authors.affiliation: Department of Gynecologic Oncology, SUNY-Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Yi-Chun
authors.initials: YC
authors.lastname: Lee
authors.affiliation: Department of Gynecologic Oncology, SUNY-Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Ovadia
authors.initials: O
authors.lastname: Abulafia
keywords: Bevacizumab; Cyclophosphamide; Endometrioid; Metronomic